Compare Citius Pharmaceuticals Inc (CTXR) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Procter & Gamble Co — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Procter & Gamble Co trades at $146.11 (market cap $340.16B). The key difference: Procter & Gamble Co is far larger — about 23235× Citius Pharmaceuticals Inc's market cap, and Procter & Gamble Co pays a 2.92% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | PG | |
|---|---|---|
Market Cap | $14.64M | $340.16B |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $167.18 |
52-Week Low | $0.53 | $138.10 |
Enterprise Value | $10.86M | $365.64B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Procter & Gamble (PG) trades at $148.37, up 0.9% on the day, with a neutral technical signal and bullish moving averages. The stock shows stable revenue near $84.3 billion in 2025 and consistent earnings beats, with a net income margin of 19.16%. Recent news highlights its dividend reliability amid market volatility, while analyst consensus leans bullish with a $161.71 price target.
PG offers steady growth and income appeal, supported by strong cash flow and a 69-year dividend growth streak. Risks include premium valuation multiples and soft demand concerns. Upside depends on execution of supply chain efficiencies and sustained margin strength in a competitive consumer staples landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
